| Ytd | -2.10% | |
| 1y | 74.83% |
| Open | 75.00 | Prev Close | 74.52 | Low | 74.49 | High | 75.40 | Mkt Cap | 14.64B |
| Vol | 481.56K | Avg Vol | 3.16M | EPS | -3.74 | P/E | N/A | Forward P/E | 141.33 |
| Beta | 0.97 | Short Ratio | 9.07 | Inst. Own | 103.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 68.73 | 200-d Avg | 68.28 | 1yr Est | 102.28 |
BBIO News
- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemod
- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemod
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-st
- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a
- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-bre
- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-bre
PALO ALTO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeB
BridgeBio will also share an oral presentation and four posters at the meeting highlighting quality
PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeB
Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and lowers t
Mid-Day Stocks: Stocks are trading lower on Wednesday, as oil and yields move higher. Once again, it
Canaccord Genuity analyst Whitney Ijem initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 202
- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to lau
BridgeBio Pharma (NASDAQ:BBIO | BBIO Price Prediction) received a Neutral initiation from Citi Neutr
Citigroup analyst Eric Joseph initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Neutral
BridgeBio Pharma NASDAQ: BBIO executives used a BofA healthcare conference appearance in Las Vegas t
BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcri
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstr
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstr
New data demonstrating disease modifying effects across clinical outcomes, biomarkers, and functiona
-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with
PALO ALTO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBi
BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript
Evercore ISI Group analyst Cory Kasimov maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperfor
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus
BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.84) per share which missed the analy
PALO ALTO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBi
PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBi
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of b
- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM stu
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceut
Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with
Mizuho analyst Salim Syed reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and maintai
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with
RBC Capital analyst Luca Issi initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Outperf
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceut
BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a biopharmaceu
Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises t
BridgeBio Pharma shares Phase 3 trial update, but early data show progress for rare muscle disease t
- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA hig
BridgeBio's rare-disease pipeline draws investor attention as new therapies near regulatory fili
JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and rais
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceut
Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and
Oppenheimer analyst Trevor Allred maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and